Aptevo Therapeutics Plunges 11.01% on $2M Offering

On April 22, 2025, Aptevo Therapeutics experienced a significant drop of 11.01% in pre-market trading, reflecting a notable shift in investor sentiment towards the biotech company.

Aptevo Therapeutics recently announced a $2 million registered direct offering, with Roth Capital Partners acting as the exclusive placement agent. The company expects the gross proceeds from this offering to be approximately $2 million, before deducting placement agent fees and other estimated offering expenses. This move is part of Aptevo's strategy to secure fresh capital for its ongoing research and development efforts, particularly in the field of cancer treatment.

Additionally, Aptevo Therapeutics has successfully closed a $2.1 million registered direct offering and a concurrent private placement, priced at-the-market under Nasdaq rules. This financial maneuver is aimed at bolstering the company's financial position and supporting its innovative projects in the biotech sector.